A5032246644- Schizophrenia research and treatment
- Mental Health and Psychiatry
- Mental Health Research Topics
- Digital Mental Health Interventions
- Pharmaceutical studies and practices
- Parkinson's Disease and Spinal Disorders
- Pharmaceutical Practices and Patient Outcomes
- Suicide and Self-Harm Studies
- Mental Health via Writing
- Clinical Reasoning and Diagnostic Skills
- Pain Management and Placebo Effect
- Glycogen Storage Diseases and Myoclonus
- COVID-19 and Mental Health
- Maternal Mental Health During Pregnancy and Postpartum
- Mental Health Treatment and Access
- Neurological disorders and treatments
- Identity, Memory, and Therapy
- Art Therapy and Mental Health
- Tryptophan and brain disorders
- Music Therapy and Health
- Child and Adolescent Psychosocial and Emotional Development
Hospital Universitario de Torrejón
2024-2025
Hospital Universitario Fundación Jiménez Díaz
2020-2024
Suicide is a public health problem worldwide, especially among adolescents. Chile one of the Latin American countries with highest suicide rates; however, few studies have investigated risk factors for attempts in this specific population. We aimed to describe suicidal behaviour Chilean adolescents and explore associated reattempts Adolescents (10-19 years) diagnosis psychiatric disorders were recruited Maule region, Chile, between 2018 2021. Sociodemographic clinical variables collected....
Eating disorders (EDs) significantly impair physical health and psychosocial functioning. Few effective therapeutic approaches exist for EDs, particularly in Anorexia Nervosa (AN). The use of ketamine, already characterized as a noncompetitive NMDA antagonist anesthetic depression suicidal ideations, could be an innovative adjuvant treatment the AN spectrum. We describe case series eight patients treated with intravenous Ketamine Adjuvant Treatment (KAT) combined usual care. also review...
Background Ecological momentary assessment (EMA) tools appear to be useful interventions for collecting real-time data on patients’ behavior and functioning. However, concerns have been voiced regarding the acceptability of EMA among patients with schizophrenia factors influencing acceptability. Objective The aim this study was investigate a passive smartphone-based app, evidence-based (eB2), spectrum disorders putative variables underlying their acceptance. Methods participants in were from...
Recovery has become a priority in schizophrenia spectrum disorders (SSDs). This study aimed to investigate predictors of objective-general functioning and disability-and subjective-quality life (QoL)-measures functional outcomes SSD.
Escobedo-Aedo, Paula Jhoana; Pans, Irene; Baca-García, Enrique; de Leon, Jose; Barrigón, María-Luisa; Ovejero, Santiago Author Information
Abstract Poor insight in schizophrenia spectrum disorders (SSD) is linked with negative outcomes. This single-centre, assessor-blind, parallel-group 1-year follow-up randomised controlled trial (RCT) tested whether metacognitive training (MCT) (compared to psychoeducation) may improve and outcomes outpatients SSD assessed: at baseline (T0); after treatment (T1) (T2). Insight (primary outcome) was measured (i) the Schedule for Assessment of Insight-Expanded version- (SAI-E), including illness...
Insight in schizophrenia spectrum disorders (SSD) is associated with outcomes. Although the neurocognitive basis of insight widely accepted, specific contribution decision-making (Jumping to Conclusions [JTC]), Cognitive (CI), and Theory Mind (ToM) remains unclear.The sample included N = 77 SSD outpatients aged 18-64 years from a randomized controlled trial metacognitive training. Assessments JTC-Beads Task, CI-Beck Scale, ToM-Hinting Emotions Recognition Test Faces.hierarchical...
<sec> <title>BACKGROUND</title> Ecological momentary assessment (EMA) tools appear to be useful interventions for collecting real-time data on patients’ behavior and functioning. However, concerns have been voiced regarding the acceptability of EMA among patients with schizophrenia factors influencing acceptability. </sec> <title>OBJECTIVE</title> The aim this study was investigate a passive smartphone-based app, evidence-based (eB2), spectrum disorders putative variables underlying their...
Introduction Paliperidone palmitate 1-month (PP1M) is a Long-acting injectable antipsychotic formulation, approved for the treatment of schizophrenia and schizoaffective disorder. Recently, paliperidone 3-months (PP3M) formulation was introduced, which maintains stability while offering longer dosing interval maintenance in patients previously treated with PP1M. Despite this, many are PP1M without transition to PP3M. Objectives To identify variables explaining instead going We hypothesize...
Introduction Concerns have been raised about ecological momentary assessment (EMA) acceptability among patients with schizophrenia spectrum disorders (SSD), which is of major relevance during the e-Mental health-focused COVID-19 pandemic. Objectives To investigate i) levels adherence to a passive smartphone-based EMA tool, Evidence-Based Behavior (eB2), SSD patients; and ii) putative predictors this. Methods Sample: (F20-29-ICD10) outpatients, age 18-64, without financial incentives,...